Long-term side effects of treatment with mTOR inhibitors in children after renal transplantation

Pediatric Nephrology

Volumn 28, Issue 8, 2013, Pages 1293-1298

  Kranz, Birgitta ^a   Wingen, Anne Margret ^b   Vester, Udo ^b   König, Jens ^a   Hoyer, Peter F ^b  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^b UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

Acute rejection; Everolimus; Growth; Pediatric renal transplantation; Pubertal development; Sirolimus

Indexed keywords

ANTIHYPERTENSIVE AGENT; CYCLOSPORIN A; ESTRADIOL; EVEROLIMUS; FOLLITROPIN; LUTEINIZING HORMONE; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; RAPAMYCIN; STEROID; TACROLIMUS; TESTOSTERONE;

ADOLESCENT; ANEMIA; APPENDICITIS; ARTERIOVENOUS FISTULA; ARTICLE; BACTERIAL INFECTION; BK VIRUS INFECTION; BONE MARROW SUPPRESSION; CHILD; CHILD DEVELOPMENT; CLINICAL ARTICLE; CYTOMEGALOVIRUS INFECTION; DRUG SAFETY; FEMALE; HERPES ZOSTER; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; INFANT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LEUKOPENIA; LYMPHOCELE; LYMPHOPROLIFERATIVE DISEASE; MALE; MOUTH ULCER; PNEUMONIA; POSTOPERATIVE PERIOD; PRESCHOOL CHILD; PRIORITY JOURNAL; PROPHYLAXIS; PROTEINURIA; PUBERTY; SALMONELLOSIS; SCHOOL CHILD; THROMBOCYTOPENIA; URINARY TRACT INFECTION;

ADOLESCENT; BODY HEIGHT; CHILD; CHILD DEVELOPMENT; CHILD, PRESCHOOL; ESTRADIOL; FEMALE; FOLLICLE STIMULATING HORMONE, HUMAN; GERMANY; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFANT; KIDNEY TRANSPLANTATION; LUTEINIZING HORMONE; MALE; PROTEIN KINASE INHIBITORS; PUBERTY; RETROSPECTIVE STUDIES; RISK FACTORS; TESTOSTERONE; TIME FACTORS; TOR SERINE-THREONINE KINASES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84879937831     PISSN: 0931041X     EISSN: 1432198X     Source Type: Journal    
DOI: 10.1007/s00467-013-2459-y     Document Type: Article

References (21)

1. North American Pediatric Renal Trial and Collaborative Studies (NAPRTCS) (2010) annual transplant report https://web.emmes.com/study/ped/annlrept/2010- Report.pdf
2. Gaumann A, Schlitt HJ, Geissler EK (2008) Immunosuppression and tumor development in organ transplant recipients: the emerging dualistic role of rapamycin. Transpl Int 21:207-217
3. Ettenger R, Hoyer PF, Grimm P, Webb N, Loirat C, Mahan JD, Mentser M, Niaudet P, Offner G, Vandamme-Lombaerts R, Hexham JM, Everolimus Pediatric Study Group (2008) Multicenter trial of everolimus in pediatric renal transplant recipients: results at three years. Pediatr Transplant 12:456-463
4. Pape L, Lehner F, Blume C, Ahlenstiel T (2011) Pediatric kidney transplantation followed by de novo therapy with everolimus, low-dose cyclosporine A, and steroid elimination: 3-year data. Transplantation 92:658-662
5. Powell HR, Kara T, Jones CL (2007) Early experience with conversion to sirolimus in a pediatric renal transplant population. Pediatr Nephrol 22:1773-1777
6. Kasap B (2011) Sirolimus in pediatric renal transplantation. Pediatr Transpl 15:673-685
7. Schwartz GJ, Haycock GB, Edelmann CM, Spitzer A (1976) A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine. Pediatrics 58:259-263
8. Schwartz GJ, Gauthier B (1985) A simple estimate of glomerular filtration rate in boys. J Pediatr 106:522-526
9. Vester U, Kranz B, Nadalin S, Paul A, Becker J, Hoyer PF (2005) Sirolimus rescue of renal failure in children after combined liver-kidney transplantation. Pediatr Nephrol 20:686-689
10. Hymes LC, Warshaw BL (2011) Five-year experience using sirolimus-based calcineurine inhibitor-free immunosuppression in pediatric renal transplantation. Pediatr Transplant 15:437-441
11. Alvarez-Garcia O, Carbajo-Pérez E, Garcia E, Gil H, Molinos I, Rodriguez J, Ordoñez FA, Santos F (2007) Rapamycin retards growth and causes marked alterations in the growth plate of young rats. Pediatr Nephrol 22:954-961
12. Aoki MS, Miyabara EH, Soares AG, Saito ET, Moriscot AS (2006) mTOR pathway inhibition attenuates skeletal muscle growth induced by stretching. Cell Tissue Res 324:149-156
13. Guba M, Pratschke J, Hugo C, Krämer BK, Nohr-Westphal C, Brockmann J, Andrassy J, Reinke P, Pressmar K, Hakenberg O, Fischereder M, Pascher A, Illner WD, Banas B, Jauch KW, SMART-Study Group (2010) Renal function, efficacy and safety of sirolimus and mycophenolate mofetil after short-term calcineurin inhibitor-based quadruple therapy in de novo renal transplant recipients: one-year analysis of a randomized multicenter trial. Transplantation 90:175-183
14. Hymes LC, Warshaw BL (2011) Linear growth in pediatric renal transplant recipients receiving sirolimus. Pediatr Transplant 15:570-572
15. Gonzalez D, Garcia CD, Azocar M, Waller S, Alonso A, Ariceta G, Mejia N, Santos F (2011) Growth of kidney-transplanted pediatric patients treated with sirolimus. Pediatr Nephrol 26:961-966
16. Höcker B, Weber LT, Feneberg R, Drube J, John U, Fehrenbach H, Pohl M, Zimmering M, Fründ S, Klaus G, Wühl E, Tönshoff B (2010) Improved growth and cardiovascular risk after late steroid withdrawal: 2-year results of a prospective, randomized trial in pediatric renal transplantation. Nephrol Dial Transpl 25:617-624
17. Boobes Y, Bernieh B, Saadi H, Al Hakim MR, Abouchacra S (2010) Gonadal dysfunction and infertility in kidney transplant patients receiving sirolimus. Int Urol Nephrol 42:493-498
18. Fritsche L, Budde K, Dragun D, Einecke G, Diekmann F, Neumayer HH (2004) Testosterone concentrations and sirolimus in male renal transplant patients. Am J Transplant 4:130-131
19. Offner G, Toenshoff B, Höcker B, Krauss M, Bulla M, Cochat P, Fehrenbach H, Fischer W, Foulard M, Hoppe B, Hoyer PF, Jungraithmayr TC, Klaus G, Latta K, Leichter H, Mihatsch MJ, Misselwitz J, Montoya C, Müller-Wiefel DE, Neuhaus TJ, Pape L, Querfeld U, Plank C, Schwarke D, Wygoda S, Zimmerhackl LB (2008) Efficacy and safety of basiliximab in pediatric renal transplant patients receiving cyclosporine, mycophenolate mofetil and steroids. Transplantation 86:1241-1248
20. Guba M, von Breitenbuch P, Steinbauer M, Koehl G, Flegel S, Hornung M, Bruns CJ, Zuelke C, Farkas S, Anthuber M, Jauch KW, Geissler EK (2002) Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 8:128-135
21. Nashan B, Citterio F (2012) Wound healing complications and the use of Mammalian target of rapamycin inhibitors in kidney transplantation: a critical review of the literature. Transplantation 94:547-561